Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz Sells 7,489 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz sold 7,489 shares of the firm’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $42.82, for a total transaction of $320,678.98. Following the completion of the transaction, the chief executive officer now directly owns 119,359 shares of the company’s stock, valued at approximately $5,110,952.38. The trade was a 5.90 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Mirum Pharmaceuticals Stock Down 1.6 %

MIRM stock opened at $41.32 on Friday. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. Mirum Pharmaceuticals, Inc. has a twelve month low of $23.14 and a twelve month high of $48.89. The company’s 50 day moving average is $42.95 and its two-hundred day moving average is $40.66. The stock has a market cap of $1.98 billion, a P/E ratio of -20.46 and a beta of 0.98.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The company had revenue of $90.38 million for the quarter, compared to analysts’ expectations of $81.99 million. During the same quarter last year, the company earned ($0.57) earnings per share. The firm’s revenue for the quarter was up 89.4% on a year-over-year basis. Research analysts expect that Mirum Pharmaceuticals, Inc. will post -1.46 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. Citigroup raised their price objective on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Leerink Partners raised their price objective on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. HC Wainwright reaffirmed a “buy” rating and issued a $66.00 target price on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Finally, Robert W. Baird raised their target price on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Mirum Pharmaceuticals has an average rating of “Buy” and an average target price of $57.10.

Institutional Trading of Mirum Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Lord Abbett & CO. LLC acquired a new stake in Mirum Pharmaceuticals during the third quarter worth approximately $28,913,000. Geode Capital Management LLC increased its holdings in shares of Mirum Pharmaceuticals by 3.2% in the 3rd quarter. Geode Capital Management LLC now owns 936,197 shares of the company’s stock valued at $36,519,000 after acquiring an additional 29,017 shares during the period. Frazier Life Sciences Management L.P. increased its holdings in shares of Mirum Pharmaceuticals by 1.2% in the 3rd quarter. Frazier Life Sciences Management L.P. now owns 6,570,392 shares of the company’s stock valued at $256,245,000 after acquiring an additional 75,000 shares during the period. Barclays PLC increased its holdings in shares of Mirum Pharmaceuticals by 4.6% in the 3rd quarter. Barclays PLC now owns 245,918 shares of the company’s stock valued at $9,592,000 after acquiring an additional 10,824 shares during the period. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of Mirum Pharmaceuticals in the 3rd quarter valued at $215,000.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.